Back to Oncology
OncologyvFDA labelEvidence-Based

Pegfilgrastim Dosing (per Label)

Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.

Clinical Input Parameters

kg
Range: 2 — 200 kg
Clinical Assessment
Awaiting Parameters
dose mg
—mg
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Pegfilgrastim Dosing (per Label) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Adult: fixed 6 mg. Pediatric: weight-band dosing per label.

Clinical Pearls & Practice Notes

  • Fixed dose per label — this tool encodes label timing rules, not a computed dose.

Evidence & Literature Citations

  1. Neulasta (pegfilgrastim) FDA Prescribing Information. Amgen Inc. Dosage: 6 mg subcutaneously once per chemotherapy cycle; pediatric weight-based dosing as labeled.

Score Interpretation Ranges

Dosed0 – pts

Pegfilgrastim dose

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.